Literature DB >> 9609524

Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

H I Sati1, J F Apperley, M Greaves, J Lawry, R Gooding, R G Russell, P I Croucher.   

Abstract

Interleukin-6 (IL-6) is an important growth factor for human myeloma cells in vitro and in vivo. However, the identity of the cells producing IL-6 in vivo in patients with multiple myeloma (MM) remains the subject of debate. We have developed a sensitive dual-colour fluorescence in situ hybridization (FISH) technique to investigate the expression of IL-6 mRNA by individual bone marrow plasma cells from patients with multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS) and healthy subjects. IL-6 mRNA could be identified in all immunoglobulin light chain (IgLC) expressing cells from all patients with MM and MGUS. The IL-6 protein could also be detected by direct immunofluorescence in all plasma cells (cytoplasmic light chain positive) from all patients with MM and MGUS. Furthermore, it was also possible to demonstrate cytoplasmic IL-6 staining of plasma cells from patients with MM by flow cytometric analysis. In contrast, neither the IL-6 mRNA or protein could be detected in normal plasma cells from healthy bone marrow donors. These data demonstrate that plasma cells from patients with MM and MGUS express the IL-6 mRNA and synthesize the IL-6 protein and support the hypothesis that autocrine synthesis of IL-6 is of importance in patients with MM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609524     DOI: 10.1046/j.1365-2141.1998.00687.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

2.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

3.  IL10 receptor is a novel therapeutic target in DLBCLs.

Authors:  W Béguelin; S Sawh; N Chambwe; F C Chan; Y Jiang; J-W Choo; D W Scott; A Chalmers; H Geng; L Tsikitas; W Tam; G Bhagat; R D Gascoyne; R Shaknovich
Journal:  Leukemia       Date:  2015-03-03       Impact factor: 11.528

Review 4.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

5.  Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.

Authors:  Julia Paton-Hough; Simon Tazzyman; Holly Evans; Darren Lath; Jenny M Down; Alanna C Green; John A Snowden; Andrew D Chantry; Michelle A Lawson
Journal:  J Bone Miner Res       Date:  2018-11-26       Impact factor: 6.741

Review 6.  The NF-κB Activating Pathways in Multiple Myeloma.

Authors:  Payel Roy; Uday Aditya Sarkar; Soumen Basak
Journal:  Biomedicines       Date:  2018-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.